Sergio Iannazzo, n/a

Senior Director, Global Market Access
argenx, Switzerland

Poster(s):

• (288) Indirect treatment comparison of efgartigimod vs immunoglobulins in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  Wednesday, October 29, 2025